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Aim: To validate a pretreatment veriﬁcation method of dose calculation and dose delivery
based on measurements with Metaplex PTW phantom.
Background: The dose-response relationships for local tumor control and radiosensitive tis-
sue complications are strong. It is widely accepted that an accuracy of dose delivery of
about  3.5% (one standard deviation) is required in modern radiotherapy. This goal is difﬁ-
cult to achieve. This paper describes our experience with the control of dose delivery and
calculations at the ICRU reference point.
Materials and methods: The calculations of dose at the ICRU reference point performed with
the  treatment planning system CMS XiO were checked by measurements carried out in the
PLEXITOMTM phantom.
All measurements were performed with the ion chamber positioned in the phantom, at
the  central axis of the beam, at depth equivalent to the radiological depth (at gantry zero
position). The source-to-phantom surface distance was always set to keep the source-to-
detector distance equal to the reference point depth deﬁned in the ICRU Report 50 (generally,
100  cm). The dose was measured according to IAEA TRS 398 report for measurements in solid
phantoms. The measurement results were corrected with the actual accelerator’s output
factor  and for the non-full scatter conditions. Measurements were made for 111 patients
and 327 ﬁelds.
Results: The average differences between measurements and calculations were 0.03%
(SD  = 1.4%), 0.3% (SD = 1.0%), 0.1% (SD = 1.1%), 0.6% (SD = 1.8%), 0.3% (SD = 1.5%) for all mea-
surements, for total dose, for pelvis, thorax and H&N patients, respectively. Only in 15 cases
(4.6%), the difference between the measured and the calculated dose was greater than 3%.
For  these ﬁelds, a detailed analysis was undertaken.Conclusion: The veriﬁcation method provides an instantaneous veriﬁcation of dose calcula-
tions  before the beginning of a patient’s treatment. It allows to detect differences smallerthan 3.5%.
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verted into an equivalent depth in the phantom according to
the scaling factor recommended by the manufacturer of the
PLEXITOMTM phantom. The source-to-phantom surface dis-
tance was always set to keep the source-to-detector distance96  reports of practical oncology a
1.  Background
The dose–response relationships for local tumour control and
radiosensitive tissue complications are strong. It is widely
accepted that the accuracy of dose delivery of about 3.5% (one
standard deviation) is required in modern radiotherapy.18 This
goal is difﬁcult to achieve.7,8 Many  measures are necessary
to minimize the uncertainty in dose delivery during patient
treatments.25 The sources of uncertainties may be divided
into four areas: geometrical errors, dosimetry errors, human
error (that may lead to both geometrical and dosimetry errors)
and, ﬁnally, errors that arise directly from equipment.19,21,23 To
minimize geometrical errors, sophisticated measurements of
reproducibility of the patient set-up combined with correction
strategies are employed.1,4 Typical human errors include irra-
diation of an incorrect patient or an incorrect site.20 These
errors are more  likely to occur in very busy radiotherapy
departments. A good example of an error linked to improper
equipment operation is the Saragossa accident.24 In many
accidents human error plays an important role.22 The uncer-
tainty in dose delivery may be analyzed by reviewing the
sequence of steps in the dose delivery chain.2,17 Alterna-
tively, it may be assessed during treatment using in vivo
dosimetry.5,16
Systematic and random errors occur in treatment delivery.
For many  years, “manual” treatments rendered radiotherapy
very open to random human errors, such as miss-read or miss-
set parameters. Many  of these were never noticed or recorded.
The number of random treatment error rates decreased con-
siderably when record and veriﬁcation systems (R&V systems)
were introduced.20 However, even with sophisticated R&V sys-
tems, some systemic errors still occur.6 For example at the
Princess Margaret Hospital in Toronto from January 1, 1997, to
December 31, 2002 there were 555 errors among 28,136 patient
treatments. Eighty-seven errors were directly attributed to
incorrect programming of the R&V system.10 Likewise, at the
University of Utah during a 1-year period, 38 errors out of
22,542 external beam treatments administered under their
R&V were identiﬁed.20 Most of them arose from incorrect man-
ual transcription of radiotherapy treatment parameters from
the planning system to the R&V system. Ideally, all systemic
errors should be detected before the start of treatment. The
correctness of dose calculations at the prescription point per-
formed with sophisticated treatment planning systems (TPS)
is often performed using an independent monitor units (MUs)
calculation programme.15 Calandrino published data from the
implementation of an independent control of MU and dis-
tribution calculation, together with a check of data reported
in the treatment chart.3 He showed that their system, which
was relatively effective in detecting systemic errors before
starting the treatment, still missed a quarter to one third
of errors. Furthermore, Calandrino’s experience conﬁrms the
utility of in vivo dosimetry in detecting previously unnoticed
systemic errors. This paper details our experience with the
control of dose delivery and calculations at the ICRU reference
point. The method relies on dose measurements, performed
at the prescription point before the start of treatment, using a
PLEXITOMTM phantom. We  present results for the 111 patients
treated with photon beams in our centre.diotherapy 1 8 ( 2 0 1 3 ) 95–100
2.  Aim
To validate a pretreatment veriﬁcation method of dose cal-
culation and dose delivery based on measurements with
Metaplex PTW phantom.
3. Materials  and  methods
The calculations of dose at the ICRU reference point (ICRURef)
performed with the treatment planning system XiO  (CMS XiO
– Release V4.40.00) were checked by measurements carried out
in the PLEXITOMTM phantom (PTW – Freiburg). The calculation
algorithm used by TPS was generally FFT (fast Fourier trans-
form) Convolution. Only in the case of the thorax region the
calculation algorithm was superposition. The phantom (see
Fig. 1) contains two eccentrically mounted rotary acrylic cylin-
ders inside a solid acrylic block. The double rotation provides
for quick and precise positioning of a detector along the cen-
tral beam axis, as well as for the off-axis measurement within
a perimeter of 12.2. The phantom is powered by two step-
per motors remotely controlled by the TBA CONTROL UNIT
(PTW – Freiburg) and by the MEPHYSTO software. The move-
ment control allows for the positioning of an ion chamber with
the accuracy of 0.5 mm.  The size of the phantom top surface
is 19.0 ×11.5 cm.  The chamber may be positioned at depths
ranging from 1.0 cm to 12.2 cm.
3.1.  Method  of  dose  measurement  at  the  ICRU
reference  point
The dose was measured separately for each treatment ﬁeld.
All measurements were performed with the ion chamber
(“0.125 ccm ﬂex.”, Type/Ser. – No. M31002 – 0594, Manufac-
turer: PTW – Freiburg, Germany) positioned at the central axis
of the beam at the radiological depth and with the UNIDOS
electrometer. The radiological depths were obtained from the
treatment plan protocols. The phantom density differs from
the density of water; therefore, the radiological depth was con-Fig. 1 – PLEXITOMTM phantom.
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Fig. 2 – Field size correction factors for non full scatter
conditions for 6 and 15 MV photon beams determined for
d = 10 cm.reports of practical oncology and
qual to the reference point depth deﬁned at the ICRU Report
013 (in most cases it was 100 cm).
Where the radiological depth was greater than the max-
mum attainable depth in the phantom (12.2 cm), additional
crylic plates of the thickness of 8 cm were placed on top of
he phantom.
The dose was measured according to IAEA TRS 398 report12
or measurements in solid phantoms. The results were cor-
ected for the actual accelerator’s output factor. They were also
orrected for the absence of full scatter as the phantom dimen-
ions do not provide full lateral scatter conditions for larger
elds. Correction factors (CF) for non-full scatter conditions
ere measured separately for 6 and 15 MV  photon beams. The
F was deﬁned as follows:
F (d, X, Y) = Dwater(d, X, Y)/Dwater(ref )
Dplexitom(drad, X, Y)/Dplexitom(ref )
, (1)
here Dwater(d, X, Y), Dplexitom(drad, X, Y) are doses measured in
he water phantom and the PLEXITOMTM phantom, respec-
ively, for open ﬁelds of (X, Y) size, at depth d, for 100 MU
nd SSD so that the source to chamber distance was 100 cm.
water(ref), Dplexitom(ref) are doses measured at reference con-
itions according to IAEA TRS 398 report12 (SSD = 90 cm,  ﬁeld
ize (10 cm,  10 cm), depth 10 cm)  in the water phantom and
n the PMMA  phantom, respectively. In the PMMA phantom,
hysical depth was 8.8 cm which is equivalent to 10.0 cm in
ater. Measurements were made for square ﬁelds with sides
f 5, 10, 15, and 20 cm at four depths 5, 10, 15, and 20 cm.  To
implify the procedure, only one CF measured at 10 cm depth
as used regardless of what the actual radiological depth of
he ICRURef was.
The dose delivered to the measurement point for a ﬁeld
ize (X, Y) at radiological depth drad was calculated as follows:
(drad, X, Y) = Mcorr(drad, X, Y) · ND,w,Q · kQ,Q0
· OF(ref )
Mcorr(ref ) · ND,w,Q · kQ,Q0
· CF(10, X, Y), (2)
here Mcorr is the measured signal corrected for temperature
nd pressure. OF(ref)  is the reference accelerator dose output
e.g. dose output put into treatment planning system), CF(10,  X,
) is correction factor for non-full scatter conditions at depth
f 10 cm.  Mcorr(ref) was measured in the PMMA phantom at
.8 cm physical depth for 10 cm square ﬁeld size. OF(ref)  was
easured in water at 10 cm depth for 10 cm square ﬁeld size.
corr(ref) and Mcorr(drad) was measured on the same day.
Because the measurements carried out to determine the
orrection for accelerator dose output and the veriﬁcation of
atient treatment ﬁelds were performed with the same ion-
zation chamber, we  can omit ND,w,Q and kQ,Qo in Eq. (2),  which
ives:
(drad, X, Y) = Mcorr(drad, X, Y) ·
OF(10,  10,  10)
Mcorr(8.8, 10,  10)
· CF(10,  X, Y),(3)
here OF(10, 10, 10)/Mcorr(8.8, 10, 10) is the correction fac-
or for the actual accelerator dose output. The measurementrad
uncertainty of a dose at a radiological depth is smaller than
1.5% (1SD).
3.2.  Measurements  for  patients
The data include measurements of doses at the ICRURef car-
ried out within 6 months for each patient treated with a radical
intent. Measurements were made on the Siemens Oncor lin-
ear accelerators for each photon treatment ﬁeld. A total of
327 ﬁelds for 111 patients were involved with tumours in the
head, neck, lung, thorax, and the pelvic areas. In order to set
up the treatment ﬁeld, the ﬁeld parameters were loaded from
the R&V system (Lantis) to an accelerator. Measurements were
always performed when the gantry was set to 0◦. The mea-
surement for a single ﬁeld was compared with the ICRURef
dose calculated with the treatment planning system. Mea-
surements were not performed if the ICRURef was not located
on the beam central axis. The difference (Diff) between the
measured and calculated dose was calculated using Eq. (4):
Diff =
(
Dmeas
Dcalc
− 1
)
· 100%. (4)
In addition, for patients for whom the measurements for
all treatment ﬁelds were made, the total dose to ICRURef was
calculated as a sum of all doses for single ﬁelds and compared
with the prescribed dose.
4.  Results
4.1.  Correction  factors  for  non-full  scatter  conditions
Fig. 2 shows correction factors for non-full scatter conditions.
Only data at radiological depth of 10 cm are presented. For
ﬁelds smaller than 15 cm × 15 cm and all depths the correction
factors differ from the ones obtained at 10 cm depth by less
than ±0.01. Only for ﬁeld sizes larger than 15 cm × 15 cm and
for depths larger than 15 cm do the correction factors differ by
±0.02. Therefore, regardless of ﬁeld size and depths, correction
factors measured at the depth of 10 cm were used.
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Table 1 – Results of pretreatment dose veriﬁcation. The mean and standard deviation (SD) values were  calculated from
results obtained for patients from one location.
Head and neck Thorax Pelvis All Total dose
Number of patients 30 35 46 111 92
Number of ﬁelds (measurements) 79 102 146 327 282
Mean (%) 0.3 0.6 0.1 0.3 0.3
Standard deviation (%) 1.5 1.8 1.1 1.4  1.0
Number of deviations >3% 2 11 2 15 0
Min–max difference (%) −3.6 to +3.2 −4.9 to +5.3 −2.2 to +3.9 −4.9 to +5.3 −2.6 to +2.9
Fig. 3 – Differences between measurements and Fig. 4 – Differences between measurements and
calculations for pelvis.
Fig. 5 – Differences between measurements and
calculations for thorax.calculations for all ﬁelds.
For 15 MV  photon beams, correction factors are smaller
than for 6 MV  photon beams. The correction factors are an
increasing function of the ﬁeld sizes. For the largest ﬁelds for
which measurements were performed, the correction factor is
close to 1.05. It would be beneﬁcial to design a larger phantom.
4.2. Dose  measurements  at  the  ICRU  reference  point
Table 1 presents information on pre-treatment measure-
ments. The results for head and neck (H&N), thorax and pelvis
regions are given separately. In the last column, the compari-
son of prescribed dose at ICRURef and the sum of all the doses
measured at this point are compared for each patient. The
total dose comparison is presented only for these patients
(92 out of 111 patients) for whom the doses for all treatment
beams were measured. The largest discrepancies between
measured and calculated doses were observed for the thorax
region. For 11 out of 102 thorax ﬁelds, the difference was larger
than 3%. In two other locations, the differences exceeded 3%
in the case of only 4 beams (4 out of 225). If the total dose is
considered, the discrepancy between the measured and the
calculated was always smaller than 3%.
Fig. 3 shows a histogram of differences between measured
and calculated doses for all ﬁelds. Figs. 4–6 present the differ-
ences between measured and calculated doses for the pelvis,
thorax and head and neck. The histograms have a Gaussian
shape.5. Discussion
As radiotherapy treatment becomes more  sophisticated, its
veriﬁcation becomes more  complex. This highly sophisticated
Fig. 6 – Differences between measurements and
calculations for head and neck.
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sreports of practical oncology and
adiotherapy results in the increasing number of possible
rrors.3,5,9,14 Errors leading to the administration of a wrong
otal dose, identiﬁed after the start of the treatment, are esti-
ated at about 30% of all detected errors.3 Thus, elimination
f these errors is of crucial importance. In this work, we
escribe a method to control dose calculation and delivery
efore the start of therapy.
The results for 111 patients and 327 treatment ﬁelds
howed a good agreement between measurement and doses
alculated with the treatment planning system. The aver-
ge differences between measurements and calculations
ere 0.03% (SD = 1.4%), 0.3% (SD = 1.0%), 0.1% (SD = 1.1%), 0.6%
SD = 1.8%), 0.3% (SD = 1.5%) for all measurements, for total
ose, for pelvis, thorax and H&N patients, respectively. In only
5 cases out of the 327 ﬁelds (4.6%), the difference between the
easured and the calculated dose was greater than 3%.
For these 15 ﬁelds, a detailed analysis was made in order to
dentify possible sources of the differences. The largest num-
er (11) was observed in the thorax region. In this location,
he dispersion of results is also the largest (−4.9% to +5.3%).
t was observed that the larger differences were observed for
ll these cases were the differences between the physical and
adiological depth were large. The largest difference between
he radiological and physical depth was 5.9 cm.  However, large
ifferences were also obtained in two cases for patients with
angential ﬁelds for breast tumours. In these cases, the calcu-
ated and measured dose differences were −4.9% and 3.7%.
he radiological depths were very small (1.4 cm and 2.2 cm
espectively). Tests performed before admission of the TPS
iO system to clinical use showed that the accuracy of sys-
em calculations was the poorest at depths close to maximum.
n the measurements reported here, a large difference was
lso obtained for one patient treated in the pelvic region. In
his case, the radiological depth for lateral ﬁelds was larger
han 20 cm.  The treatment beams also passed through thick
emoral heads and some pelvic bone.
The last two ﬁelds, for which differences were greater than
%, were in the head area. In one case the difference was 3.2%
nd we  did not identify a speciﬁc reason that might account
or such a large difference. In the other case, there was a lack
f lateral scattered radiation (the tumour was located near a
kin surface) which could affect the accuracy of calculations.
In some cases, an additional factor inﬂuencing the differ-
nce between the measured and calculated doses might be
blique incidence of the treatment ﬁeld. The surface of the
bsorber was ﬂat, which changed the scattered conditions –
he contribution of the scattered dose to calculated and mea-
ured dose was a little different.
In many  radiotherapy centres, dose delivered from a single
eld is controlled with in vivo dosimetry. A measurement from
he in vivo detector on a patient’s skin surface is compared
ith the calculated dose at depth.11 This method allows for
etection of most large errors made in dose calculations and
uring dose delivery. However, there are many  limitations of
his method, one being its rather low sensitivity to smaller dif-
erences. As ESTRO notes,11 most of radiotherapy departments
ave a 5% ﬁxed tolerance level for in vivo dosimetry. Thus, dif-
erences between measured and calculated doses of less than
% are regarded as acceptable. A second limitation is a rather
mall speciﬁcity of in vivo dosimetry, which, in practice, givesotherapy 1 8 ( 2 0 1 3 ) 95–100 99
a large number of false positive results. Patient movement  (e.g.
respiratory motion) may inﬂuence the measurement. Also, it
may be quite difﬁcult to place a detector accurately in some
cases (e.g. presence of hairs).
The action level of in vivo dosimetry is most often of 5%.11
The dose veriﬁcation method proposed in this paper allows
for a lower action level, namely 3.5%. Another advantage of
the method is that a simple analysis of the geometrical situa-
tion allows a determination of whether the difference between
measurement and calculation results leads to an overestima-
tion or underestimation of the measurement result. Thus,
when a measurement exceeds the action level, a relatively
simple review of the clinical situation and measuring system
will, in many  cases, allow one to decide whether to accept
the result or to proceed with a more  detailed analysis. The
approach here does not extend the treatment time, because
measurements are made prior to therapy being initiated. The
time of a single measurement for one ﬁeld was, typically, about
5 min. It could be much shorter with improvements to the
phantom.
The most important advantage of the method is that it
allows for detection of errors before the treatment com-
mences. Its disadvantage is that it does not allow for detection
of errors made in SSD determination. However, it should be
noted that, although in vivo dosimetry is considered to be a
method allowing for detection of SSD errors, in practise only
large differences in SSD, those amounting to more  than a few
centimetres, can be discovered. It is much easier to check the
appropriateness of an SSD setting by visual inspection. Due
to the fact that the measurement is made for gantry angle 0◦
it is not possible to check the angular instability of the dose
rate. To the best of our knowledge, the angular instability of
the dose rate of modern accelerators has never been discov-
ered with in vivo dosimetry. An important limitation of the
proposed method is the impossibility to verify the use of the
proper immobilization equipment, bolus or plates for blocks.
Other advantages of the method described here arise from
the need to take account of the instability of an accelerator.
Therefore, this method is an ideal indirect tool for verifying
the accuracy of calculations of a treatment planning system
at the beam central axis. Our results show that the XiO  treat-
ment planning system calculates the central axis dose with a
high accuracy. In addition, with this method, if something goes
wrong one can repeat measurements in the same dosimetry
session. In case of in vivo dosimetry, measurements cannot
be repeated until the next fraction. Finally, an extremely valu-
able feature of the proposed method is the ability to verify if a
given dose differs signiﬁcantly from the prescribed dose, even
where in vivo measurement is not possible, e.g. PA ﬁelds.
If not permanently, it may be used as a quality control
method at the beginning of the clinical use of a new treatment
planning system.
6.  ConclusionsDose veriﬁcation measurements at radiological depth by
means of a PLEXITOMTM phantom can be recommended as
a powerful tool to improve safety of radiotherapy, especially
in centres where the treatment is carried out under control of
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a R&V system. Being a sensitive method, it allows detection of
differences smaller than 3.5%. The method provides instan-
taneous veriﬁcation of dose calculations before the beginning
of treatment. The greatest advantage of the dose veriﬁcation
with the PLEXITOMTM phantom is that it allows veriﬁcation
of dose calculation and delivery directly to the ICRU refer-
ence point. Additionally, the method provides an indirect
veriﬁcation of the accuracy of calculations performed with a
treatment planning system. Our results show that XiO sys-
tem calculates doses on the central axis with high accuracy.
The disadvantage of the proposed method is that it does not
allow for veriﬁcation errors resulting from mistakes in deter-
mining the SSD or mistakes resulting from an improper use of
immobilization tools and boluses.
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